1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GSK Tries To Chase Down Pfizer With Phase III Pentavalent Meningococcal Vaccine Data

 
• By Joseph Haas

Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.

GSK Exit
GSK's pentavalent meningococcal vaccine hits its Phase III endpoints • Source: Shutterstock

GSK plc said it plans to file a pentavalent vaccine candidate for meningococcal infections, MenABCWY, a combination of its on-market vaccines Bexsero and Menveo, for approval following a successful Phase III trial, the data from which were released on 14 March. First, however, GSK must file a supplemental biologic licensing application for full US approval of Bexsero.

The pharma was not specific on timing, but its candidate is already behind Pfizer Inc.’s pentavalent meningococcal vaccine, which has an October action date at the US Food and Drug Administration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows more promise in slowing idiopathic pulmonary fibrosis.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

More from R&D

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.